Evgen Pharma PLC Publication of data on SFX-01 in glioblastoma
10 Novembre 2021 - 8:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
10 November 2021
Evgen Pharma plc
("Evgen" or the "Company")
Peer reviewed publication of data on SFX-01 in glioblastoma
Substantial pre-clinical data set generated by collaborators at
the University of Aquila and other Italian centres.
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company developing sulforaphane based medicines for the treatment
of multiple diseases, notes the publication of data in preclinical
models of glioblastoma (GBM) generated by Dr Claudio Festuccia and
colleagues at the Universities of Aquila, Rome and Rieti, Italy
(Colapietro et al, Pharmaceuticals, 2021, 14, 1082).
GBM, also known as glioblastoma multiforme, is an aggressive
type of cancer (a type of malignant glioma) that can occur in the
brain or spinal cord. GBM is very difficult to treat, and a cure is
most often not possible; treatments generally slow progression of
the cancer and reduce signs and symptoms. The average survival time
is 12-18 months, with only 25% of glioblastoma patients surviving
more than one year, and only 5% of patients surviving more than
five years.
The in vitro data, in GBM cells and patient-derived
glioma-initiating cells, show anti-tumour activity of the Company's
lead asset SFX-01. The work goes on to show in vivo anti-tumour
activity in both sub-cutaneous and orthotopic xenograft (tumour
cell lines are implanted in the brain) models of GBM. In both
models, SFX-01 reduced tumour growth substantially and demonstrated
statistically significant improved survival. The in vitro work was
complemented by a recent pre-print publication from a different
laboratory, the University of Auckland, New Zealand, in patient
derived cells and 3D spheroid models of GBM (Leung et al 2021).
Evgen recently announced the grant of Orphan Drug Designation in
the USA for Malignant Glioma, affording the programme additional
data protection and other incentives.
Dr Huw Jones, CEO of Evgen, commented: "We are very pleased to
see the publication of this important work by Dr Festuccia and
colleagues. The data generated underpin our decision to focus on
glioblastoma as one of our core programmes. Our design work on a
Phase 2 study in glioblastoma patients is well advanced and we are
discussing the design with a number of prominent UK and European
clinical centres. In due course we hope to contribute a new
treatment option for patients with this devastating disease."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7876 741 001 / + 44 (0)7867
Anna Dunphy / Phillip Marriage 984 082
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The has its headquarters at Alderley Park, Cheshire, and its
registered office is at the Liverpool Science Park, Liverpool. It
is listed on the AIM market of the London Stock Exchange and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUKVNRASUARAA
(END) Dow Jones Newswires
November 10, 2021 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Ott 2023 a Ott 2024